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Abstract: Deregulation of cell growth and development lead to cancer, a severe condition that
claims millions of lives worldwide. Targeted or selective approaches used during cancer treatment
determine the efficacy and outcome of the therapy. In order to enhance specificity and targeting
and obtain better treatment options for cancer, novel modalities are currently under development.
Photodynamic therapy has the potential to eradicate cancer, and combination therapy would yield
even greater outcomes. Nanomedicine-aided cancer therapy shows enhanced specificity for cancer
cells and minimal side-effects coupled with effective cancer destruction both in vitro and in vivo.
Nanocarriers used in drug-delivery systems are very capable of penetrating the cancer stem cell
niche, simultaneously killing cancer cells and eradicating drug-resistant cancer stem cells, yielding
therapeutic efficiency of up to 100-fold against drug-resistant cancer in comparison with free drugs.
Safety precautions should be considered when using nano-mediated therapy as the effects of extended
exposure to biological environments are still to be determined.
Keywords: cancer; cancer therapies; cancer recurrence; stem cells; porphine-related macrocycles;
enhanced targeting; nanomedicine
1. Introduction
Cancer is a major cause of death worldwide, with a projected increase to 19.3 million new cases in
the year 2025 with the most vulnerable being the low- and middle-income populations [1]. In normal
scenarios, the regulation of both cell growth and development signals operates well and permits the
induction of tolerance, resistance, or cell death response after exposure to both external and internal
stimuli [2]. Defective regulation leads to excessive cell growth, abnormal apoptosis, carcinogenesis, and
eventually tumor metastasis and cancer. Defects in the mechanisms of apoptosis are primordial for tumor
initiation, tumor proliferation, and metastatic progression [3]. Tumor or cancer cells have the capability to
undergo cell survival beyond the normal life expectancy and atypically multiply with a higher level of cell
proliferation than normal cells. Most current cancer therapies are good at targeting neoplastic cells and
affecting fast-proliferating cells, including normal cells of skin, hair, and gastrointestinal cells. The search
for novel and targeted-cancer therapies is justified by the inability of current treatments to effectively
cure cancer without damaging normal cells [4]. Other cancer therapies are effective in eradicating cancer
but only partly or temporally before tumor recurrence [5]. Tumor recurrence is predictable in most cases,
owing to acquired drug-resistance or the development of cancer stem cells [6].
Cancer recurrence can be a useful tool to assess the suitability of cancer burden and treatment.
Nowadays, large numbers of cancer deaths occur as a result of cancer recurrence in patients
who had previously completed treatment programs and thereafter appeared to be disease-free [7].
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Cancer recurrence is the reappearance and manifestation of cancer after a period known as remission,
a post-treatment and disease-free period [8]. Usually, recurrent cancers are worse and thought
to be more aggressive than their previous states. The fact that there is no precise duration of
remission, shorter periods make it difficult to differentiate recurrence from cancer progression.
The fear of cancer recurrence is an uprising concern among patients and can be predicted by a
thorough analysis of certain factors [8,9]. Cancer recurs as the result of some cancer cells that remain
unaffected after treatment and later become detrimental, causing either local, regional, or distant
symptoms. Therefore, proper cancer selectivity or targeting approaches stand as essential criteria
for any cancer therapy [10]. Inappropriate drug-targeting is one of the most common causes of
cancer drug resistance to conventional treatments [11]. Others mechanisms of direct or indirect
drug resistance in human cancer may include drug efflux, drug inactivation, DNA damage repair,
cell death inhibition, epigenetics, and epithelial-mesenchymal transition. Any or a combination of these
mechanisms render unwanted cells capable of tolerating therapeutic agents, developing drug tolerance
or resistance, which can be graded as disease-specific or evolutionarily conserved (microorganisms
and humans) [11,12]. The search for effective treatment modalities is encouraged with treatment
combination allegedly more effective than taking any treatments separately. Such combinations are
thought to be able to counteract intrinsic or acquired drug resistance of cancer cells [13–15].
According to the stem cell theory of cancer, a marginal and undifferentiated side-population
of cells known as cancer stem cells (CSCs) or tumor initiation cells (TICs), possessing stem-like
properties, could be held responsible for initiating, propagating, and sustaining cancer [16]. On top
of the characteristic features of normal stem cells, CSCs possess tumorigenic phenotypes such as
multidrug resistance, uncontrolled growth and proliferation, tissue invasion, epithelial-mesenchymal
plasticity, and high levels of expression of anti-apoptotic proteins and drug efflux pumps [17,18].
They are capable of renewing themselves, differentiating into other cells, spending extended time
in the non-dividing G0 cell cycle stage, and exhibiting altered phenotypes. Such modifications
confer to CSC the ability to differentiate from common cancer cells, to overexpress certain drug
efflux transporters, and to develop multiple drug resistance, cancer recurrence, and metastasis [19].
A correlation has been established between epithelial-mesenchymal transition (EMT)-type cells, CSC,
and microRNAs (miRNAs). A miRNA is a short and non-coding RNA molecule that can play a
crucial role in RNA silencing and post-transcriptional regulation [20]. EMT cells possess CSC-like
characteristics, and CSC displays a mesenchymal phenotype. Both the formation of CSC and the
acquisition of an EMT phenotype are connected by the expression of aberrant miRNAs. Effective cancer
treatments targeting miRNAs should be able to affect the regulation of EMT that could cause the
suppression of CSC or EMT-type cells, as miRNAs appeared to be the essence of the cause of drug
resistance and cancer recurrence, see Figure 1.
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Figure 1. The role of stem cells in carcinogenesis, cancer metastasis, and drug-resistance.
The dysregulation of the Notch favors the mesenchymal to epithelial transition of stem cells over the
epithelial to mesenchymal one, leading to the decrease of E-cadherin and increase of free beta-catenin,
and subsequent stimulation of tumoral and migratory functions, which can be mediated by certain
proteins, such as enhancer of zeste homologue-2 protein.
2. Cancer Therapy: Photodynamic Therapy as a Solution for Cancer Relapse
2.1. Conventional Cancer Therapies
Surgical resection and chemotherapy are the most common conventional cancer treatments
and cure less than 50% of all patients with cancer [21]. Surgical resection is the most effective
treatment with almost 45% of cases cured after the entire or partial removal of affected organs [22].
When not removed, the exposure of malfunctioning organs to chemotherapeutic agents, causes damage
to rapidly proliferating cells, both neoplastic cells as well as normal cells in the bone marrow,
macrophage, digestive tract, and hair follicles [23,24]. The degree of the side effects enforces the
necessity for modification of treatment parameters, such as changes in dosage, in time intervals
between repeats, or simply discontinuing the chemotherapeutic program due to the low survival rates
after therapy [23,25,26]. Numerous side effects, nonspecific targeting, and poor delivery of anticancer
agents are motives for novel and effective cancer therapy modalities, which aim to identify and treat
solely cancer cells.
2.2. Photodynamic Therapy
Photodynamic therapy (PDT) is a treatment approach suitable for certain types of conditions
which are not cured by surgical resection and include various cancer types. PDT is considered
as a promising treatment modality, presenting significant effectiveness and limited side effects,
while numerous side effects are associated with chemotherapy [27,28]. In PDT, a non-toxic agent
known as photosensitizer (PS) is administered and taken up by tumor cells, before being activated
by light of a specific wavelength that matches its absorption properties. Then, light-activated PS
induces selective damage to tumors and surrounding vasculature in the presence of molecular oxygen,
see Figure 2 [28]. The success of PDT solely depends on the choice of PSs, characterized by chemical
purity, activation with a wavelength appropriate for tissues (near the infrared region), selectivity to
neoplastic cells, and development of a long-lived triplet excited state. Some of the good examples
of PSs used in PDT are methylene blue, hematoporphyrin, chlorins, photodithazine, curcumin,
phthalocyanines, and hypericin [28–30]. Type I or type II reactions can result from an effective
activation of PS in the presence of molecular oxygen. Type I reaction is related to a low oxygen level
in treated tissues (neoplastic), and depends on the interaction between the triplet excited state of PS
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(3PS*) and the treated tissues, which act as a substrate for 3PS*. This interaction generates radicals,
which are able to interact with oxygen to produce reactive oxygen species (ROS). Generated ROS cause
damage to the treated tissues and, subsequently, result in cell death [31,32]. Type II reaction is related
to a high level of oxygen in treated tissues (commonly human neoplastic), and depends on the direct
interaction between the triplet excited state of PS (3PS*) and oxygen to generate a singlet excited state
of oxygen. The latter is a highly reactive and toxic molecule, able to readily damage treated tissues and
cause subsequent cell death [31,33,34]. The induced cell death response is dependent on the subcellular
localization of PS. A mitochondria-localized PS would likely induce an apoptotic response whereas
PS that localized in lysosomes induces an apoptotic response via cleavage of BID and/or a necrotic
response after a supra-lethal PDT dose [35]. In order to enhance their therapeutic efficiency, PSs are
constantly being developed and improved by conjugating them with other molecules. Previously,
PDT was restricted to superficial conditions due to the inaccessibility of light into deeper areas.
Recent developments indicated that PDT would now be suitable for both conditions, including brain
and liver cancers, by means of a novel wireless device that activate PSs [36].Nanomaterials 2018, 8, x FOR PEER REVIEW  4 of 13 
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Figure 2. One of the processes by which photosensitizer (PS) molecules accumulate in cells with
phosphatidylethanolamine in both inner and outer leaflets of the lipid bilayer membranes, like in
cancer cells. Laser irradiation activates PS and reactions, leading to the generation of reactive oxygen
species (ROS) and cell destruction.
2.3. Tetrapyrrolic Photosensitizers
Among the most commonly used PSs for PDT, those with tetrapyrrolic structures are
particularly interesting. They are natural pigmented molecules with four pyrrole rings, joined by
carbon-carbon interactions, and both linear and cyclic tetrapyrroles may be found. The linear
form may or may not undergo configurational changes such as stereochemical, homosequential,
or stereohomosequential changes and/or Fischer-Rosanoff conventions to give rise to their cyclic
counterparts [37]. Porphyrins have important biochemical properties and are derived from porphine,
an organic aromatic and heterocyclic compound, consisting of four pyrrole rings, which is an essential
ring system, see Figure 3a [38,39]. Another compound with a central aromatic ring structure is
chlorin, which contains at its core three pyrroles and displays no aromaticity throughout its perimeter,
see Figure 3b [40].
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Obtained through the cyclotetramerization of phthalic acid derivatives and phthalimides,
phthalocyanines are structurally similar to porphyrins and porphyrazines [41]. This family of
tetrapyrrolic structures with incorporated central metal ions is also used for the treatment of
non-invasive cancers, and designated as a second generation of PSs with improved photophysical and
photodynamic properties over those of porphyrins. These tetrapyrrolic macrocycles strongly absorb
light in the near-infrared region of the visible spectrum and are proven to effectively kill malignant
tumors during PDT [42–44]. One of the major downfalls of this family of PSs is the lack of adequate
water solubility. This issue can be overcome by adding charged particles, carbohydrates, or peptide
ligands to the periphery of phthalocyanines to give rise to third generation PSs [44].
2.4. Enhanced Targerting Approach
As discussed earlier, miRNAs play essential roles in cancer development as well as regulatory
roles by targeting mRNA for cleavage or translational repression. The increased expression
level of miRNA-210, miRNA-296, and induced apoptosis related-miRNA were demonstrated after
PDT-mediated treatment of Hela cells. PDT-prompted hypoxia led to a subsequent increased
expression of miRNA-210 as well as vascular endothelial growth factor (VEGF). The miRNA-210
is a predominant miRNA activated under hypoxic environments. VEGF stimulated the expression
of miRNA-296 and restored blood supply to cells that have become deprived of oxygenated
blood [45,46]. Thus, PDT causes damage to the tumor microenvironment, which is both a cause
and consequence of tumorigenesis. An effective cancer treatment should be able to stimulate biological
processes such as ROS generation, hypoxia, and VEGF regulation of angiogenesis to target the tumor
microenvironment and prevent cancer [47]. The efficiency of PDT was established after assessing its
impacts on the miRNome with the overexpression of phototoxic-miRNAs 130a, 93, 25, or inhibition of
resistive-miRNAs 20a, 141, 200a, 200c, and 203, which all improved the vulnerability of insensitive cell
lines (drug-resistant) towards PDT [27].
3. Nanomedicine for Better Cancer Therapy
Nanotechnology is a multidisciplinary field and has emerged from the junction of chemistry,
biology, applied physics, optics, digital analysis, and materials science. This evolving and
interdisciplinary field mainly involves the design, characterization, manufacture, manipulation,
and application of structures at the nanometer scale (nano: one billionth). Such structures are known
as nanoparticles and are of particular interest as seen by the growing popularity and publications
on nanoparticles or nanomaterials [48–50]. These can be attributed to their physicochemical features,
among which are their rigidity, hydrophobicity, size, and charge, which portray this technology
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as tremendously potent in solving societal issues including health-related ones [51]. When used
to monitor, repair, and regulate molecular activities of human biological systems, it is known as
nanomedicine; the specialized application of nanotechnology to achieve a reliable diagnosis as
well as effective therapy. It includes aspects such as nanoparticle drug delivery, which currently
constitutes an extensively studied area and shows potentialities for both molecular nanotechnology
and nano-vaccinology [52–55]. The increased attractiveness of nanoparticles mediated-therapy rests on
the abilities of nanomaterials to deliver hydrophobic-like treatment to diseased areas by overcoming
biological barriers [56]. Noble metal nanoparticles comprise gold, silver, and platinum nanoparticles
and are of particular interest in providing such treatments. They exhibit localized surface plasmon
resonance due to their strong optical absorption and scattering propensities. They can readily interact
with biomolecules equally at the membrane surface and inside cells. Such nanoparticles can enhance
specific signals during diagnosis and are able to effectively treat critical illness such as bony and
dental conditions, various cancers, diverse infections, tuberculosis, human immunodeficiency virus,
Parkinson’s disease, and many more [57,58].
3.1. Nanoparticles and Drug-Delivery
Nanoparticles used for medical applications are multifunctional, and the drug-delivery function
is undoubtedly the most frequently used. The utilization of nano-carriers during cancer therapy
alleviates the non-specific accumulation and side effects of anticancer drugs into normal cells, thus,
offering better tumor targeting and enhancement of therapeutic efficiency. The increasing utilization of
nanoparticles in drug-delivery is justified by the inadequacy of conventional therapeutic agents alone
to target affected tumor tissues and effectively treat the condition. Currently used nano-drug delivery
systems include micelles, dendrimers, liposomes nanotubes, and various other carriers (polymeric-,
solid lipid-, viral-, gold-, and magnetic-carriers) [59,60]. Such nanoparticles-specific delivery could
be achieved by two routes known as passive and active targeting [61]. The first is more common
and based on two distinctive characteristics of the tumor microenvironment, namely, the enhanced
permeability and retention (EPR) effect and acidic conditions. The EPR effect is triggered by the high
metabolic capacities of tumor cells and ever-developing neovascularization, which is often porous
with gap junctions between endothelial cells. It is through these breaches that passive targeting
becomes possible and nano-carrier systems selectively accumulate in tumor cells. In order to meet
the high energy demand of ever-proliferating cells, the high oxygen demand causes the activation of
the glycolytic pathway, resulting in an acidic extracellular tumor environment. Once incorporated in
tumor cells, which are in acidic surroundings, nano-carrier systems like liposomes disintegrate and
release therapeutic agents. The active routes aim to reinforce selective targeting and overcome the
problems occurring during passive targeting such as the mucosal barrier and non-specific drug-delivery.
Thus, active nano-carrier systems are made even more specific to tumor cells through conjugation to
biomolecules including ligands and antibodies [59,62–64].
3.2. Essential Bonding in Carrier-Systems
The usage of targeted anticancer agents aims to improve the therapeutic outcomes and release the
active form of the drug at its lowermost dose with minimal activity loss and side effects. The prolonged
accumulation of drugs into cancer cells and their subsequent improved therapeutic index are counted
among the direct benefits of targeted anticancer therapy. Thus, the nature of bioconjugation and bonds
between the carriers and drugs in one hand, and between carriers-drug systems and cancer cells on the
other hand, are of crucial importance [48]. Both covalent and non-covalent interactions are employed
to assemble an effective anticancer drug-delivery complex. Amide bond formation on the surface
of nanocarriers is achieved via a stable chemical reaction. Minimal activity loss, high stability and
dispersion of resulting complexes in an aqueous environment, prolonged biodistribution, and large
accumulation in cancer cells, as well as enhanced therapeutic outcomes, can be obtained using modified
targeted delivery systems [48,65,66].
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Thioester bond formation between nanocarriers and ligands yields high selectivity of delivery
systems and prolonged biodistribution. Such formation requires adequate chemical reactions,
with potential molecular rearrangement and disulfide bond formation [67,68]. Disulfide bonds could
occur following conjugation of ligands and nanocarriers, and these delivery systems may well possess
a stronger affinity for cancer cells [67,69]. Hydroxyl groups attached to ligands, render them able to
interact with hydrazide groups of nanocarriers, forming acetyl-hydrazine bonds. Such modifications
bring control and stability to the whole system and enable it to last in blood and a high immunological
environment [48]. Another way to increase the affinity to cancer cells is to modify ligands by the
Diels-Alder reaction to yield bicyclic products. The same reaction can also be used to bond ligands
to nanocarriers [67–70]. On the other hand, non-covalent interactions are fragile linkages with the
delivery systems and simply broken during treatment. The increasing possibility of ending up
with side-products after the modification of delivery systems is becoming a quality and safety issue.
Often neglected after assembling processes, purification steps are required and the click chemistry
may provide purification options for such systems before their use in targeted cancer therapy [71].
Despite significant progress in cancer management observed over the past years, the curative
efficiency has not improved concurrently. This may be due to a minor CSCs population with
distinctive abilities, responsible for treatment resistance, metastatic growth, and tumor recurrence [72].
Thus, the existence of CSCs is a major obstacle for cancer treatment and more efforts have to be
consented to develop cancer therapies that concurrently target CSCs. Certainly, a possible and
promising route to achieve such an objective is to use nanomedicines to increase CSCs sensitivity
and the efficacy of anti-CSCs treatments [71]. The role of CSCs in self-renewal, proliferation,
tumor progression, drug resistance, recurrence, and metastasis in many neoplastic conditions could be
minimized by using nanoparticles for better delivery of anti-cancer agents but also targeting CSCs,
thus achieving prevention of drug-resistance as well as cancer recurrence. Besides the delivery role,
nanomaterials improve the stability and increase the bioavailability of anti-CSCs agents, decrease
drug-resistance ability of CSCs, and reduce side effects on normal stem cells [73,74]. Nano-carriers
used in drug-delivery systems are highly capable of penetrating the CSC niche and enhancing the
therapeutic efficiency by up to 100-fold against drug-resistant lymphoma, breast and prostate cancer
in comparison with free drugs. Nano-carriers do so by altering pathways involved in self-renewal and
differentiation of CSCs, CSC proliferation as well as regulation of metabolic activities of drug-resistant
cells and drug-efflux transporters [19,73,75–77]. By using nano-carriers in therapy, it is possible to
simultaneously kill cancer cells and eradicate drug-resistant CSCs both in vitro and in vivo [78].
4. Nanoparticles in Combined Therapy: Health Promoter or Health Hazards
Similarly to other noble metals, gold nanoparticles (GNPs) have outstanding potential in
enhancing the efficacy of cancer therapy, due to their ability to exhibit exclusive physiochemical
and optical features, particularly their plasmonic properties. Thus, they are utilized in targeted drug
and gene therapy; and their roles include the incorporation of PSs in multi-component delivery systems
and the facilitation of PS’s transcytosis across epithelial and endothelial barriers. PDT is emerging as
a therapeutic solution for cancer and other diseases. However, several PSs used in PDT are highly
hydrophobic and require carrier systems to enhance cellular targeting and uptake by the cell. GNPs can
enhance not only the cellular uptake of PSs but also the singlet oxygen generation and efficiency of
PDT [79,80]. The usage of GNPs and subsequent localized surface plasmon have been recognized as
reasons for the enhancement and efficiency of combined therapeutic approaches. GNPs-mediated
cancer therapy had offered great specificity and minimal side-effects coupled with effective cancer
destruction both in vitro and in vivo [81–83].
Although the use of GNPs and other nanomaterials have shown beneficial properties for the
management of cancers among other conditions, clarification on a number of safety issues is still
needed. First, the exact amount of nanomaterials in targeted diseased areas should be determined
prior to the proper determination and application of other parameters such as irradiation of the
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targeted areas during combination therapies. The irradiation of deep cancer tissues and monitoring
of the therapy still require much technological development to assess the targeted cellular sites [84].
Contrary to PSs, nanoparticles are toxic to cells to some extent [85,86], as shown in Table 1. The lack of
proper safety and evaluation tools for nanoparticles during cancer therapy constitutes a major setback.
The use of immunomodulatory and enhanced surface modification approaches could help to alleviate
the potentially hazardous effects of certain nanoparticles such as the metal nanoparticles [54,71,73].
Due to their relatively small sizes, nanoparticles are easily taken up by cells and could lead to an
exponential increase, extended accumulation, cell damage, and, eventually, nano-pollution in the hosts.
The multiple active agents in nanoparticles blends and possible diverse biological behaviors make it
difficult when undergoing standard drug analysis, thus constituting a hurdle for advanced medical
applications. Nanoparticles are mostly used as delivery agents rather than actual therapeutic agents
and there is very little research on the effect of nanoparticles post-delivery. Any potentially good
therapeutic approach using such materials for delivery purposes should provide a clear indication of
their removal from biological systems. The absence of such a provision renders the use of nanoparticles
as ambiguous in any cancer therapeutic approach, especially for clinical trials and further applications.
Small sized nanomaterials (1–30 nm) should readily be cleared via the kidney route, while larger ones
are taken up by Kupffer cells and macrophages for excretion by the liver or spleen [59]. Early in vitro
evidence showed that nanomaterials remained in cellular compartments for up to three weeks before
being cleared by exocytosis [71]. The determination of the resulting impact of such delayed clearance
would elucidate the influence of this technology in the battle against cancer.
Table 1. Potential applications and toxic effects of nanomaterials.
Types Name Main Applications Toxicity and Affected Structures References
Metallic Aluminumoxide
Fuel cells, polymers, paints,
coatings, textiles, biomaterials
Cell viability, mitochondrial
functions, oxidative stress, protein
expression, genotoxicity
[87,88]
Metallic Gold, easilyfunctionalized Drug-carriers, contrast agents
Relatively safe, non-toxic
spherical core [50,89]
Metallic Copper oxide
Antibacterial agents,
semiconductors, heat transfer
fluids, contraceptive devices
Cell membrane integrity,
oxidative stress, liver, kidney,
spleen, genotoxicity
[90–92]
Metallic Silver
Antibacterial agents, wide range
of commercial products, wound
dressing, coating surgical
instruments, prostheses
Cell viability, cell membrane
integrity, oxidative stress, kidney,
liver, lung, genotoxicity
[93–95]
Metallic Zinc oxide
Wave filters, UV (Ultra-Violet)
detectors, gas sensors,
sunscreen, body care products
Cell viability, cell membrane
integrity, mitochondrial functions,
oxidative stress, liver, genotoxicity
[96–98]
Metallic Iron oxide Drug-carriers, diagnostic agents
Cell viability, mitochondrial
functions, oxidative stress, brain,
liver, lung, genotoxicity
[99–101]
Metallic Titanium oxide Pigment and coloring agents
Oxidative stress, immune
function, lung, liver, kidney,
spleen, genotoxicity
[102–104]
Non-Metallic Carbon-basedand Fullerenes carbon nanotubes
Cell viability, cell membrane
integrity, liver, kidney, bone,
spleen, genotoxicity
[105–108]
Non-Metallic Silica, easyfunctionalized
Drug-carriers (easy
functionalized)
Oxidative stress, cell membrane
integrity, mitochondrial functions,
genotoxicity
[109–111]
Non-Metallic Polymers(biodegradable) Drug-carriers
Relatively safe, non-toxic,
non-immunologic,
non-inflammatory, least toxicity
[112]
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5. Conclusions
The success observed with the use of conventional therapeutic approaches to cancer is mostly
due to early screening and diagnosis. Late detection and increasing prevalence of drug resistant
cancers require further research and treatment development. Nanomedicine used in conjunction with
other upgraded therapies would be a better alternative for cancer eradication, providing that all the
setbacks and clarifications are dealt with. The preeminence of nanomedicine in cancer therapy over
current treatment options will continue to increase and possibly result in the effective eradication of
drug-resistant cancers. Nanoparticles-based medical applications have already shown tremendous
benefits in fighting various conditions. In cancer therapy, this new technology offers the potential to
alleviate the persisting problems of cancer recurrence and drug-resistance. GNPs stand as distinguished
intracellular targeting carriers due to size-tailoring, multiple surface-functionalities, and exceptional
light-dependent features. The fantasy of the prolonged effects of nanoparticles in desired cells, tissues,
and organs creates a safety issue, which is the major limitation; therefore, rendering the technology
unattractive for some advanced applications. Purification of delivery systems post-modification, as
well as post-delivery clearance, seem to be ignored. Whether nanomedicine is a boon or bane for
cancer therapy, can only be addressed after further investigation and expansion of the technology.
However, the feasibility of this technology leaves plenty of room for improvement and modification to
achieve a strong affinity to cancer cells, render delivery systems able to endure immunologic attacks
and yield even better therapeutic outcomes. Nanomedicine is the future of cancer therapy as it offers
the prospect to overcome the current limitations, which require detailed insights for specific targeting
approaches, improved cellular uptake for all tumors, including CSC populations, and an optimal
remedy with enhanced efficiency.
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